For any trial-based outcome relied (Based on (From Subsection C.4 (Alternative Step 3a) on in the economic evaluation with corresponding if extrapolation is any extrapolation from the time extrapolation of required) horizon of the trial(s) only duration of treatment, if any) For any important outcome (Include here any (From Subsection C.4 (Alternative Step 3a) generated for or by the economic modelled increases if possible, or if this evaluation from the trial-based in the provision of approach is used, outcome(s) (‘transformation of some resources and explain why a nature of outcome’ only) any modelled presentation here is offsetting decreases not possible) of others) For the final outcome relied on in (Should not change (From Subsection C.4 (Alternative Step 3a) the economic evaluation from Step 2 if possible, or if this generated as a valuation of the because nature of approach is used, trial-based outcome(s) (‘value outcome does not explain why a transformation’ only) change) presentation here is not possible) For the final outcome relied on in (Completed Step 3 the economic evaluation and expected base combining any extrapolation from case) the time horizon of the trial(s) with XXX any transformation of the (Step 3) outcome(s) > Subsections to the MSAC Therapeutic Guidelines. Comment on the ICER and whether it accurately represents the cost-effectiveness, given the methodology used, of listing the intervention. Consider which step in the economic evaluation appears to contribute most to the final ICER. If the SBA presents Markov traces or other model traces, present those here. If the SBA has not presented model traces and they provide some insight into what is driving the model, then present them here and comment. Comment on whether the model traces make sense do they correspond to empirical data, or – what would be expected with the disease or condition? Has the SBA presented univariate (one-way) sensitivity analyses on all variables using plausible extremes of values, and justified the selection of those extreme values? Has the SBA tabulated all univariate sensitivity analyses alongside the base case?
For any trial-based outcome relied on in the economic evaluation with any extrapolation from the time horizon of the trial(s) only (Based on corresponding extrapolation of duration of treatment, if any) (From Subsection C.4 if extrapolation is required) (Alternative Step 3a) For any important outcome generated for or by the economic evaluation from the trial-based outcome(s) (‘transformation of nature of outcome’ only) (Include here any modelled increases in the provision of some resources and any modelled offsetting decreases of others) (From Subsection C.4 if possible, or if this approach is used, explain why a presentation here is not possible) (Alternative Step 3a) For the final outcome relied on in the economic evaluation generated as a valuation of the trial-based outcome(s) (‘value transformation’ only) (Should not change from Step 2 because nature of outcome does not change) (From Subsection C.4 if possible, or if this approach is used, explain why a presentation here is not possible) (Alternative Step 3a) For the final outcome relied on in the economic evaluation combining any extrapolation from the time horizon of the trial(s) with any transformation of the outcome(s) (Completed Step 3 and expected base case) XXX (Step 3) > Subsections to the MSAC Therapeutic Guidelines. Comment on the ICER and whether it accurately represents the cost-effectiveness, given the methodology used, of listing the intervention. Consider which step in the economic evaluation appears to contribute most to the final ICER. If the SBA presents Markov traces or other model traces, present those here. If the SBA has not presented model traces and they provide some insight into what is driving the model, then present them here and comment. Comment on whether the model traces make sense – do they correspond to empirical data, or what would be expected with the disease or condition? Has the SBA presented univariate (one-way) sensitivity analyses on all variables using plausible extremes of values, and justified the selection of those extreme values? Has the SBA tabulated all univariate sensitivity analyses alongside the base case?
MSAC%20Assessment%20Report%20Critique%20Template%20-%20Therapeutic.docx